Skip to main content

Published locations for In MS, serious adverse effects are more common in rituximab versus ocrelizumab

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. In MS, serious adverse effects are more common in rituximab versus ocrelizumab

User login

  • Reset your password
  • /content/ms-serious-adverse-effects-are-more-common-rituximab-versus-ocrelizumab
  • /neurologyreviews/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common
  • /multiplesclerosishub/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common
  • /jcomjournal/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common-rituximab
  • /neurology/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common-rituximab
  • /neurology/msresourcecenter/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more
  • /breast-cancer-icymi/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common
  • /b-cell-lymphoma-icymi/article/228425/multiple-sclerosis/ms-serious-adverse-effects-are-more-common